Reactome | JAK3 binds JAK3 inhibitors

JAK3 binds JAK3 inhibitors

Stable Identifier

R-HSA-9679028

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Janus Kinase 3 (JAK3) binds and is inhibited by several small molecule drugs (Clark et al. 2014, Changelian et al. 2003, Flanagan et al. 2010, Dhillon 2017, Chi et al. 2020). The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases such as baricitinib, tofacitinib, ruxolitinib and tofacitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Literature References

PubMed ID	Title	Journal	Year
29139090	Tofacitinib: A Review in Rheumatoid Arthritis Dhillon, S	Drugs	2017
24417533	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases Clark, JD, Flanagan, ME, Telliez, JB	J. Med. Chem.	2014
31918398	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma Chi, F, Chen, L, Wang, C, Li, L, Sun, X, Xu, Y, Ma, T, Liu, K, Ma, X, Shu, X	Bioorg. Chem.	2020
14593182	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Changelian, PS, Flanagan, ME, Ball, DJ, Kent, CR, Magnuson, KS, Martin, WH, Rizzuti, BJ, Sawyer, PS, Perry, BD, Brissette, WH, McCurdy, SP, Kudlacz, EM, Conklyn, MJ, Elliott, EA, Koslov, ER, Fisher, MB, Strelevitz, TJ, Yoon, K, Whipple, DA, Sun, J, Munchhof, MJ, Doty, JL, Casavant, JM, Blumenkopf, TA, Hines, M, Brown, MF, Lillie, BM, Subramanyam, C, Shang-Poa, C, Milici, AJ, Beckius, GE, Moyer, JD, Su, C, Woodworth, TG, Gaweco, AS, Beals, CR, Littman, BH, Fisher, DA, Smith, JF, Zagouras, P, Magna, HA, Saltarelli, MJ, Johnson, KS, Nelms, LF, Des Etages, SG, Hayes, LS, Kawabata, TT, Finco-Kent, D, Baker, DL, Larson, M, Si, MS, Paniagua, R, Higgins, J, Holm, B, Reitz, B, Zhou, YJ, Morris, RE, O'Shea, JJ, Borie, DC	Science	2003
21105711	Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection Flanagan, ME, Blumenkopf, TA, Brissette, WH, Brown, MF, Casavant, JM, Shang-Poa, C, Doty, JL, Elliott, EA, Fisher, MB, Hines, M, Kent, C, Kudlacz, EM, Lillie, BM, Magnuson, KS, McCurdy, SP, Munchhof, MJ, Perry, BD, Sawyer, PS, Strelevitz, TJ, Subramanyam, C, Sun, J, Whipple, DA, Changelian, PS	J. Med. Chem.	2010